22nd Century Group, Inc (NASDAQ:XXII) Stock Short Interest Jumps 3,074.8%

22nd Century Group, Inc (NASDAQ:XXII) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 1,198,947 shares, an increase of 3,074.8% from the October 15th total of 37,764 shares. Based on an average daily trading volume, of 63,446,721 shares, the short-interest ratio is currently 0.0 days. Approximately 13,321.6% of the company’s stock are sold short.

22nd Century Group Price Performance

Shares of NASDAQ:XXII opened at $1.42 on Wednesday. The company’s fifty day moving average price is $57.49 and its 200 day moving average price is $1,877.52. 22nd Century Group has a 12 month low of $1.40 and a 12 month high of $22,446.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.61 and a quick ratio of 1.90. The firm has a market capitalization of $12,780.00, a P/E ratio of -0.00 and a beta of 0.76.

22nd Century Group (NASDAQ:XXII) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($904.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($348.00) by ($556.80). 22nd Century Group had a negative net margin of 27.04% and a negative return on equity of 69.37%. The company had revenue of $2.86 million during the quarter, compared to analyst estimates of $7.48 million.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 22nd Century Group in a report on Monday, October 26th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, 22nd Century Group currently has a consensus rating of “Sell”.

About 22nd Century Group

22nd Century Group, Inc. was a biotechnology company focused on developing tobacco products with reduced nicotine content. Its research centered on genetically modified tobacco plants and cigarette formulations designed to lower nicotine exposure and support smoking cessation or harm-reduction efforts. The company’s principal product was VLN cigarettes, which were made with very low nicotine tobacco and marketed as containing substantially less nicotine than conventional cigarettes. 22nd Century also historically developed and commercialized other reduced-nicotine cigarette products, including Quest, and pursued applications of its plant-science technology in the tobacco and cannabinoid sectors.